Compounds > n-(3-(aminomethyl)benzyl)acetamidine
Page last updated: 2024-10-21

n-(3-(aminomethyl)benzyl)acetamidine and Cardiomyopathies

n-(3-(aminomethyl)benzyl)acetamidine has been researched along with Cardiomyopathies in 1 studies

N-(3-(aminomethyl)benzyl)acetamidine: structure in first source
N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.

Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Matsuhisa, S1
Otani, H1
Okazaki, T1
Yamashita, K1
Akita, Y1
Sato, D1
Moriguchi, A1
Iwasaka, T1

Other Studies

1 other study available for n-(3-(aminomethyl)benzyl)acetamidine and Cardiomyopathies

ArticleYear
N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster.
    Antioxidants & redox signaling, 2008, Volume: 10, Issue:12

    Topics: Acetylcysteine; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Benzylamines; Cardiomyop

2008